Does Weight Loss From Semaglutide and Tirzepatide Cost You Muscle? A Systematic Review Weighs In
A review of 35 trials finds incretin drugs cut fat but often exceed expected muscle loss. Whether this harms function is still unmeasured.
Résumé
GLP-1–based drugs such as semaglutide and tirzepatide drive major weight loss, but clinicians worry some of it is muscle rather than fat. This systematic review examined 35 randomized trials of liraglutide, semaglutide, tirzepatide, or dulaglutide that measured body composition. People on incretin drugs consistently lost fat mass and visceral fat. However, muscle-related measures accounted for a median of 28.3% of total weight lost, and about two thirds of studies exceeded prespecified benchmarks for expected muscle loss. Lifestyle or placebo groups that lost weight also often exceeded the benchmarks, though they lost far less weight overall. No trial measured physical function, so whether these lean mass losses matter clinically remains unknown. The trials were short, small, and too varied to combine statistically.
Résumé détaillé
Incretin-based therapies are among the most widely prescribed weight-loss drugs, and they produce large reductions in body weight. A key concern, especially for older adults and anyone focused on healthspan, is that rapid weight loss may take disproportionate amounts of fat-free mass and skeletal muscle. Muscle supports metabolic health, mobility, and resilience with aging.
The authors searched six databases and trial registries from 2003 to February 2026 for English-language randomized trials of liraglutide, semaglutide, tirzepatide, or dulaglutide in adults that reported body composition. From 8,102 records, 35 studies qualified. They had a median duration of 26 weeks and a median of 78 participants. Body composition was measured by BIA, DXA, CT, or MRI. The authors compared observed muscle-related losses with prespecified benchmarks: about 25% of total weight loss for fat-free or lean soft tissue mass, and about 15% for skeletal muscle on CT or MRI.
Incretin groups lost more weight than placebo or lifestyle comparators, with consistent reductions in total fat and visceral adiposity. Muscle-related indices accounted for a median of 28.3% of total weight loss (IQR 15.9% to 39.9%), and 65% of incretin groups exceeded the benchmark. Among comparator groups that lost weight, a median of 2.5% of body weight was lost, and 38% of these exceeded the benchmarks. No study reported objective physical function.
The findings suggest that lean mass loss is common with incretin therapy, but it is also common with other weight loss, so these drugs are not clearly unique in this respect. The clinical meaning is unclear because function was never measured.
Caveats include short follow-up, small trials, only 42.9% at low risk of bias, and body composition as a primary outcome in only 10 studies. Methods and reporting varied too much for meta-analysis. Fat-free mass also includes water and organ tissue, so it is an imperfect proxy for muscle. These results come from the abstract only.
Principales conclusions
- Across 35 randomized trials, incretin therapies consistently reduced total fat mass and visceral adiposity alongside greater weight loss than comparators.
- Muscle-related indices made up a median 28.3% of total weight loss in incretin groups (IQR 15.9% to 39.9%).
- About 65% of incretin groups exceeded the prespecified benchmark for expected muscle-related loss.
- Weight-losing lifestyle or placebo comparators also exceeded benchmarks in 38% of cases, despite much smaller median weight loss of 2.5%.
- No included trial reported objective physical function, so the functional consequences of lean mass loss remain unknown.
Méthodologie
Systematic review of English-language randomized controlled trials from 2003 to February 2026 across six databases and registries, with a preregistered protocol on the Open Science Framework. Thirty-five trials of liraglutide, semaglutide, tirzepatide, or dulaglutide were synthesized narratively against prespecified muscle-loss benchmarks, because heterogeneity precluded meta-analysis.
Limites de l'étude
Trials were short (median 26 weeks) and small, only 42.9% were at low risk of bias, and body composition was a primary outcome in just 10 studies. Differing measurement methods (BIA, DXA, CT, MRI) prevented meta-analysis, and the benchmarks are prespecified approximations rather than validated thresholds. No physical function data were available, and an erratum was issued for the article, so the published version should be checked.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :